Sugar Land, Texas — According to state and local development sources, QuVa Pharma Inc. plans to invest $3,000,000.00 to build out 23,600 square feet of new space in Sugar Land. The company plans to occupy the new space at 12620 W Airport Blvd, Suite 130 in Sugar Land, on or about April 1, 2025. According to the company website QuVa Pharma is a leader in 503B outsourced compounding, serving all 50 states with a full portfolio of sterile, ready-to-administer injectable products. QuVa was purpose-built to change the 503B industry for the better and is leading the way in making it more safe, efficient, and reliable. With unmatched expertise in cGMPs and sterile pharmaceutical manufacturing, we achieve higher than required quality and safety standards and maintain a leading FDA compliance record, so hospitals can more confidently and reliably focus on patient care. While our leading cGMP processes, sterile-to-sterile portfolio, and expansive capacity of 340,000 sq ft across five facilities are the foundation of success, it is our transparency, customer-focused service, and contracted supply arrangements that enable us to help hospitals and health systems better meet their patient care and operational needs. As FDA compliance becomes more stringent, QuVas ability to reliably supply the highest-quality products is more valuable than ever and allows hospitals to spend more time on patient care and less time worried about beyond use dates, waste, workload inefficiencies, and compliance. That is why QuVa is proud to be recognized as the partner of choice for many of the nations leading health systems. So, whether you are calling for a response or being called on for a solution, know that QuVa is accountable, and in us, you always have an answer.

To learn more about QuVa Pharma Inc., visit http://www.quvapharma.com/

Company Contact:
Stuart Hinchen, Chief Executive Officer
stuart.hinchen@quvapharma.com
https://www.linkedin.com/in/stuarthinchen/
888-339-0874

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.